Trial Profile

A phase III, double-blind, insulin-combination therapy study of imeglimin (TIMES 3)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imeglimin (Primary) ; Insulin
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms TIMES 3
Sponsors Poxel; Sumitomo Dainippon Pharma

Most Recent Events

18 Apr 2022 Results assessing efficacy and safety of imeglimin for up to 52 weeks as combination therapy with insulin in Japanese patients with type 2 diabetes, published in the Diabetes, Obesity and Metabolism.
22 Mar 2022 According to Poxel media release, data from this study were published at Diabetes Obesity and Metabolism in Jan 2021.
23 Jun 2021 According to Poxel media release, a new drug application for TWYMEEG Tablets 500mg3 for the treatment of type 2 diabetes, was approved in Japan supported by positive results from the Phase 3 TIMES program

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com